$ZTS (Zoetis Inc.)

$ZTS {{ '2016-02-16T13:50:18+0000' | timeago}} • Webcast

$ZTS said for 2016 it is projecting 2-4% operational revenue growth, which reflects the impact of its SKU reduction and changes to its operations in Venezuela. Excluding these impacts, The company also said it expects to grow revenue 8-10% operationally with 2 percentage points coming from the regional performance.

$ZTS {{ '2017-06-16T17:01:44+0000' | timeago}} • Announcement

Nexvet Biopharma, $ZTS, and Zoetis Belgium jointly dispatched a letter to the holders of convertible securities of Nexvet in accordance with Rule 15 of the Irish Takeover Rules to provide information regarding how the Acquisition of Nexvet by $ZTS will affect such securities.

$ZTS {{ '2017-05-11T20:52:27+0000' | timeago}} • Announcement

$ZTS BoD declared 3Q17 dividend of $0.105 per share, payable to holders of the company’s common stock. The dividend is payable on Sept. 1, 2017, to holders of record on June 15, 2017.

$ZTS {{ '2017-05-11T11:47:10+0000' | timeago}} • Announcement

$ZTS announced a plan to expand capacity at its Global Manufacturing and Supply facility in Kalamazoo, Mich. $ZTS will install two new production lines and related operations to manufacture oral tablet and chewable medicines for companion animals. $ZTS expects to add up to 45 manufacturing positions in the next 3 years.

$ZTS {{ '2017-05-04T12:18:44+0000' | timeago}} • Announcement

In 1Q17, $ZTS' revenue in the US segment was $605MM, a growth of 4% YoY. Meanwhile, revenue in the International segment rose 8% on a reported basis and 9% operationally to $615MM.

$ZTS {{ '2017-05-04T12:14:52+0000' | timeago}} • Announcement

$ZTS reaffirmed its guidance for FY17. Revenue is expected between $5.1Bil and $5.225Bil, while EPS is estimated between $2.08 and $2.20. Adjusted EPS is predicted in the range of $2.26-2.36.

$ZTS {{ '2017-05-04T12:11:09+0000' | timeago}} • Announcement

Animal health company $ZTS posted 17% improvement in net income in 1Q17, helped by a 6% hike in revenue to $1.2Bil. Net income was $238MM, or $0.48 per share, compared to $204MM, or $0.41 per share in the year-over period. On an adjusted basis, $ZTS earned $0.53 per share.

$ZTS {{ '2017-04-27T13:42:42+0000' | timeago}} • Announcement

$ZTS said the European Commission has granted the company marketing authorization for Cytopoint (lokivetmab). Cytopoint is indicated to treat the clinical signs, including itching and inflammation, associated with atopic dermatitis in dogs of any age weighing 3 kilograms or more.

$ZTS {{ '2017-04-13T14:44:27+0000' | timeago}} • Announcement

$ZTS will acquire $NVET for $6.72 in cash per ordinary share, which values the entire issued and to be issued ordinary share capital of Nexvet at approx $85MM. This per share purchase price represents a 66% premium over Nexvet’s April 12, 2017 closing price. The acquisition will be completed in H2 of 2017.

$ZTS {{ '2017-02-16T14:30:06+0000' | timeago}} • Announcement

$ZTS said the European Commission has granted the company a license for Stronghold Plus (selamectin/sarolaner), a topical combination of parasiticides that treats ticks, fleas, ear mites, lice and gastrointestinal nematodes and prevents heartworm disease in cats.

$ZTS {{ '2017-02-16T14:23:52+0000' | timeago}} • Webcast

$ZTS expects to exceed its target of $300MM in savings for 2017. Also for the year, the company has planned to initiate direct-to-consumer marketing and advertising campaigns in the U.S. for its animal products.

$ZTS {{ '2017-02-16T14:17:40+0000' | timeago}} • Webcast

$ZTS said it has returned $488MM in excess capital to shareholders through dividends and share repurchase in 2016. In addition, the company has announced $1.5Bil multi-year share repurchase program beginning in 2017.

$ZTS {{ '2017-02-16T13:02:34+0000' | timeago}} • Announcement

For FY17, $ZTS expects revenue to be in the range of $5.100-5.225Bil. The company expects reported diluted EPS to be between $2.08-2.20 per share. Adjusted diluted EPS is expected to be about $2.26-2.36.

$ZTS {{ '2017-02-16T13:00:43+0000' | timeago}} • Announcement

During 4Q16, $ZTS's revenue in the U.S. segment was $631MM, 1% down compared with 4Q15, reflecting the impact of fewer calendar days and product rationalizations. Revenue in the International segment rose 2% to $636MM, the growth reflects the impact of product rationalizations.

$ZTS {{ '2017-02-16T12:55:16+0000' | timeago}} • Announcement

Animal health company $ZTS 4Q16 reported increased net income of $154MM, or $0.31 per share, compared to $22MM, or $0.04 per share during 4Q15. Revenue was flat at $1.27Bil. Excluding items, $ZTS earned $0.47 per share.

$ZTS {{ '2017-02-15T13:14:37+0000' | timeago}} • Announcement

The BoD of $ZTS has declared a 2Q17 dividend of $0.105 per share of its common stock. The dividend will be paid on June 1, 2017, to shareholders of record on April 6, 2017.

$ZTS {{ '2017-01-03T17:41:54+0000' | timeago}} • Announcement

PHARMAQ, a business of $ZTS, announced the acquisition of the Norwegian  company Nordland Sett Vaks. Nordland Sett Vaks is an innovator in the manufacture and marketing of high quality vaccination machinery for the aquaculture industry. Terms of the transaction were not disclosed.

$ZTS {{ '2016-12-22T11:51:01+0000' | timeago}} • Announcement

$ZTS said the U.S. Department of Agriculture granted it license for Cytopoint, first monoclonal antibody therapy approved to help provide sustained control of clinical signs associated with atopic dermatitis in dogs. Cytopoint provides fast, effective relief of itching and offers sustained efficacy and convenience of 1 injection every 4 to 8 weeks.

$ZTS {{ '2016-12-07T13:40:37+0000' | timeago}} • Webcast

$ZTS' BoD authorized a $1.5Bil multi-year share repurchase program as part of its long-term capital allocation plans. The BoD also declared a 1Q17 dividend of $0.105 per share, up 10.5% from a year ago, payable on Wednesday, March 1, 2017, to holders of record on Friday, Jan. 20, 2017.

$ZTS {{ '2016-11-02T13:03:33+0000' | timeago}} • Webcast

$ZTS' companion animal product sales grew 9% to $490MM, helped by increased sales in APOQUEL, an allergy drug, and other new launches. Livestock products sales declined 2% to $735MM.

$ZTS {{ '2016-11-02T11:27:27+0000' | timeago}} • Announcement

$ZTS expects FY17 revenue to be in the range of $5.150-$5.275Bil. Diluted EPS is expected to be in the range of $2.10-2.22 on a reported basis, or $2.28-2.38 on an adjusted basis.

Recent Transcripts

SRPT (Sarepta Therapeutics, Inc.)
Wednesday, July 19 2017 - 8:30pm
JNJ (Johnson & Johnson)
Tuesday, July 18 2017 - 12:30pm
NVS (Novartis AG)
Tuesday, July 18 2017 - 12:00pm
PRGO (Perrigo Company Public Limited Company)
Wednesday, May 31 2017 - 12:30pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
ICCC (ImmuCell Corp.)
Thursday, May 11 2017 - 8:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
ZTS (Zoetis Inc.)
Thursday, May 4 2017 - 12:30pm
HSKA (Heska Corporation)
Tuesday, May 2 2017 - 3:00pm
PFE (Pfizer Inc.)
Tuesday, May 2 2017 - 2:00pm
ADM (Archer-Daniels-Midland Company)
Tuesday, May 2 2017 - 1:00pm
MRK (Merck & Co. Inc.)
Tuesday, May 2 2017 - 12:00pm
IDXX (IDEXX Laboratories, Inc.)
Friday, April 28 2017 - 12:30pm
SRPT (Sarepta Therapeutics, Inc.)
Thursday, April 27 2017 - 8:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
ABAX (Abaxis, Inc.)
Thursday, April 27 2017 - 8:15pm

AlphaGraphics you may like